I-Mab Enters Clinical Collaboration With Bristol Myers Squibb To Evaluate Claudin 18.2 x 4-1BB Bispecific Antibody Givastomig Combination; No Terms Disclosed
Portfolio Pulse from Benzinga Newsdesk
I-Mab has entered a clinical collaboration with Bristol Myers Squibb to evaluate the combination of givastomig, an investigational bispecific antibody, with nivolumab and chemotherapy for treating advanced Claudin 18.2-positive gastric and esophageal cancers. The study will be a multi-national Phase 1 trial conducted by I-Mab, with Bristol Myers Squibb supplying nivolumab.
June 05, 2024 | 11:02 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bristol Myers Squibb is collaborating with I-Mab to supply nivolumab for a Phase 1 trial evaluating a new cancer treatment combination.
The collaboration with I-Mab to supply nivolumab for a new cancer treatment could enhance Bristol Myers Squibb's portfolio and potentially lead to new revenue streams if the trial is successful.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
I-Mab has entered a clinical collaboration with Bristol Myers Squibb to evaluate a new cancer treatment combination in a Phase 1 trial.
The collaboration with Bristol Myers Squibb to evaluate a new cancer treatment combination could significantly boost I-Mab's research capabilities and market presence if the trial is successful.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90